Swiss Cardiac Amyloidosis Registry Swiss-CARE Studying Heart Disease in Amyloidosis Using Cardiac MRI to Guide Treatment

What this Trial Is About

Cardiac transthyretin amyloidosis ATTR is a condition where misfolded transthyretin protein deposits in the heart, causing thickening of the heart walls and leading to heart dysfunction and failure. Researchers are investigating imaging markers using cardiac magnetic resonance CMR techniques like feature tracking and T1- and T2-mapping to better understand disease severity and identify patients who may benefit from treatment that stabilizes transthyretin. The study collects detailed CMR imaging data from patients with amyloidosis, including measures of heart function and tissue characteristics, over an 18-month period after therapy begins. Clinical and laboratory follow-up visits occur every 3 to 6 months. This observational research gathers retrospective and prospective data from patients diagnosed at a single hospital to evaluate how these imaging markers relate to disease progression and treatment response. Participants undergo regular assessments including CMR scans to measure left and right ventricle function, tissue changes, and extracellular volume. The study aims to use these imaging results to predict major adverse cardiac events over a five-year period. Researchers will also monitor clinical status and laboratory values during follow-up visits to better understand the impact of treatment and disease progression.

Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)